Ficha de revisão: Understanding Heart Failure Types and Pathophysiology

📋 Course Outline

1. Heart Failure Types
2. Heart Failure Pathophysiology
3. Clinical Manifestations
4. Diagnostic Tests
5. Laboratory Markers
6. Pharmacological Treatments
7. Non-Pharmacological Management
8. ECG Basics
9. ECG Waveform Components
10. ECG Abnormalities in HF

📖 1. Heart Failure Types

🔑 Key Concepts & Definitions

• Heart Failure (HF): A clinical syndrome where the heart's ability to pump blood is inadequate to meet the body's needs, resulting in symptoms like dyspnea and edema.

• Systolic Heart Failure (HFrEF): Heart failure characterized by reduced ejection fraction (<40%), due to impaired ventricular contraction.

• Diastolic Heart Failure (HFpEF): Heart failure with preserved ejection fraction (>50%), caused by impaired ventricular relaxation and filling.

• Ejection Fraction (EF): Percentage of blood ejected from the left ventricle during systole; used to classify HF types.

• Left-sided Heart Failure: Failure involving the left ventricle, leading to pulmonary congestion and respiratory symptoms.

• Right-sided Heart Failure: Failure involving the right ventricle, causing systemic venous congestion and peripheral edema.

📝 Essential Points

• HF is classified into systolic and diastolic types based on EF and ventricular function.
• Systolic HF is often caused by ischemic heart disease, myocardial infarction, or cardiomyopathies.
• Diastolic HF is frequently associated with hypertension, obesity, and aging, with stiff ventricles impairing filling.
• The clinical presentation varies: left-sided HF presents with pulmonary symptoms, right-sided with systemic congestion.
• Accurate classification influences treatment choices; for example, ACE inhibitors are effective in HFrEF, while managing comorbidities is key in HFpEF.
• Echocardiography is essential for differentiating HF types by assessing EF and ventricular function.

💡 Key Takeaway

Heart failure is categorized into systolic (reduced EF) and diastolic (preserved EF) types, each with distinct pathophysiology and management strategies, making accurate diagnosis vital for effective treatment.

📖 2. Heart Failure Pathophysiology

🔑 Key Concepts & Definitions

• Heart Failure (HF): A clinical syndrome where the heart's ability to pump blood is inadequate to meet the body's metabolic needs, leading to symptoms like dyspnea and edema.

• Systolic Heart Failure: A type of HF characterized by reduced ejection fraction (<40%), due to impaired ventricular contraction and decreased cardiac output.

• Diastolic Heart Failure (HFpEF): Heart failure with preserved ejection fraction (>50%), caused by impaired ventricular relaxation and filling, despite normal contractile function.

• Neurohormonal Activation: Compensatory mechanisms involving the sympathetic nervous system and renin-angiotensin-aldosterone system (RAAS) that initially maintain cardiac output but eventually contribute to cardiac remodeling and worsening HF.

• Cardiac Remodeling: Structural changes in the heart (e.g., hypertrophy, dilation) in response to injury or stress, which impair cardiac function over time.

• Preload and Afterload: Preload refers to ventricular stretch at end-diastole; afterload is the resistance the heart must pump against. Both influence cardiac workload and failure progression.

📝 Essential Points

• Heart failure results from impaired systolic or diastolic function, leading to inadequate tissue perfusion and congestion.

• Neurohormonal systems (e.g., sympathetic nervous system, RAAS) are activated in HF to compensate but cause detrimental effects like hypertrophy and fibrosis.

• Cardiac remodeling is a key pathological process that worsens heart function; therapies aim to inhibit this process.

• Increased preload and afterload increase myocardial workload, exacerbating HF; managing volume status and vascular resistance is crucial.

• The pathophysiology involves a vicious cycle: decreased cardiac output leads to neurohormonal activation, which worsens myocardial damage and functional decline.

💡 Key Takeaway

Heart failure arises from complex neurohormonal and structural changes that impair the heart's ability to pump effectively, with compensatory mechanisms ultimately contributing to disease progression. Effective management targets these maladaptive processes to improve outcomes.

📖 3. Clinical Manifestations

🔑 Key Concepts & Definitions

• Dyspnea: Shortness of breath resulting from pulmonary congestion or decreased cardiac output, common in left-sided heart failure.
• Orthopnea: Difficulty breathing when lying flat, relieved by sitting up; indicates pulmonary congestion.
• Paroxysmal Nocturnal Dyspnea (PND): Sudden nighttime breathlessness causing awakening, due to fluid redistribution when lying down.
• Peripheral Edema: Swelling in lower extremities or other dependent areas caused by fluid retention, typical in right-sided heart failure.
• Jugular Venous Distension (JVD): Visible elevation of the jugular vein when the patient is at 45 degrees, indicating increased right atrial pressure.
• Hepatomegaly: Enlarged liver due to congestion from right-sided failure, often accompanied by abdominal discomfort.

📝 Essential Points

• Clinical signs reflect the underlying pathophysiology: pulmonary symptoms (dyspnea, crackles) indicate left-sided failure; systemic signs (edema, JVD) suggest right-sided failure.
• Symptom severity correlates with NYHA functional classification, guiding treatment and prognosis.
• Recognizing early manifestations like exertional dyspnea is crucial for timely intervention.
• Congestion-related symptoms are often exacerbated by activity or positional changes.
• Physical examination findings such as crackles, S3 gallop, and displaced apical pulse support diagnosis.

💡 Key Takeaway

Clinical manifestations of heart failure result from impaired cardiac function leading to pulmonary and systemic congestion; early recognition of these signs is vital for prompt management and improved patient outcomes.

📖 4. Diagnostic Tests

🔑 Key Concepts & Definitions

• Echocardiogram: A non-invasive ultrasound imaging technique that visualizes heart structures and assesses function, including ejection fraction (EF), chamber size, and wall motion abnormalities. It is the gold standard for diagnosing heart failure.

• B-type Natriuretic Peptide (BNP): A hormone produced by the ventricles in response to increased wall stretch and volume overload. Elevated BNP levels (>100 pg/mL) support the diagnosis of heart failure and help differentiate cardiac from non-cardiac causes of dyspnea.

• Electrocardiogram (ECG): A recording of the heart's electrical activity used to detect arrhythmias, ischemia, conduction abnormalities (e.g., bundle branch blocks), and other cardiac conditions associated with heart failure.

• Chest X-ray: Imaging modality used to identify cardiomegaly, pulmonary congestion, and edema, which are indicative of heart failure severity.

• Laboratory Tests (Troponin, Electrolytes, Renal Function): Troponin levels assess myocardial injury; electrolytes and renal function tests monitor effects of heart failure and medications, and guide treatment adjustments.

📝 Essential Points

• Echocardiography is essential for confirming heart failure diagnosis, determining EF, and guiding treatment decisions.
• BNP levels assist in diagnosing heart failure, especially in patients with ambiguous symptoms, and can monitor response to therapy.
• ECG abnormalities such as LBBB, atrial fibrillation, or ischemic changes provide insight into underlying cardiac pathology and influence management.
• Chest X-ray findings like cardiomegaly and pulmonary edema correlate with clinical severity.
• Laboratory tests help differentiate heart failure from other causes of dyspnea and assess organ involvement or damage.

💡 Key Takeaway

Accurate diagnosis of heart failure relies on a combination of imaging, biomarker, electrical, and laboratory assessments, enabling targeted treatment and improved patient outcomes.

📖 5. Laboratory Markers

🔑 Key Concepts & Definitions

• B-type Natriuretic Peptide (BNP): A hormone produced by ventricular myocardium in response to increased wall stress and volume overload. Elevated BNP levels (>100 pg/mL) are indicative of heart failure severity.

• N-terminal pro-BNP (NT-proBNP): The inactive fragment released during BNP synthesis; levels correlate with heart failure severity and are used for diagnosis and prognosis.

• Troponins (Troponin I and T): Cardiac-specific proteins released into the bloodstream during myocardial injury. Elevated levels suggest ischemia or infarction, which can precipitate or complicate heart failure.

• Serum Electrolytes (Na+, K+, Mg2+): Imbalances are common in heart failure due to diuretics and neurohormonal activation; critical for arrhythmia risk and management.

• Renal Function Tests (Creatinine, BUN): Assess kidney function, which is often impaired in heart failure due to decreased perfusion, influencing medication dosing and prognosis.

• Liver Function Tests: Elevated liver enzymes may indicate hepatic congestion secondary to right-sided heart failure.

📝 Essential Points

• BNP and NT-proBNP are primary biomarkers for diagnosing and assessing the severity of heart failure; higher levels correlate with worse outcomes.
• Troponin elevation in heart failure patients indicates myocardial injury, which may worsen prognosis.
• Electrolyte disturbances (hyponatremia, hypokalemia) are common in heart failure and can precipitate arrhythmias.
• Renal impairment is prevalent in heart failure, necessitating careful monitoring of kidney function to guide therapy.
• Laboratory markers assist in differentiating cardiac from non-cardiac causes of dyspnea and in monitoring treatment response.

💡 Key Takeaway

Laboratory markers such as BNP, troponins, electrolytes, and renal function tests are vital tools in diagnosing, assessing severity, and guiding management of heart failure, ultimately improving patient outcomes through targeted interventions.

📖 6. Pharmacological Treatments

🔑 Key Concepts & Definitions

• ACE Inhibitors (Angiotensin-Converting Enzyme Inhibitors): Medications that block the conversion of angiotensin I to angiotensin II, leading to vasodilation, reduced afterload, and decreased cardiac workload. They improve survival in heart failure patients.

• Beta-Blockers: Drugs that antagonize beta-adrenergic receptors, reducing sympathetic nervous system activity. They decrease heart rate, myocardial oxygen demand, and improve cardiac function and survival in heart failure.

• Diuretics: Agents that promote fluid excretion via the kidneys, alleviating symptoms of volume overload such as edema and pulmonary congestion. Commonly used diuretics include furosemide and hydrochlorothiazide.

• Aldosterone Antagonists: Potassium-sparing diuretics like spironolactone that block aldosterone effects, reducing myocardial fibrosis and mortality in heart failure with reduced ejection fraction.

• Vasodilators: Medications such as nitrates that dilate blood vessels, decreasing preload and afterload, thereby improving cardiac efficiency and symptom relief.

• Inotropes: Drugs like dobutamine that increase myocardial contractility, used in acute decompensation but not for long-term management due to increased mortality risk.

📝 Essential Points

• Pharmacological management aims to reduce mortality, improve symptoms, and prevent hospitalizations.
• The cornerstone drugs are ACE inhibitors, beta-blockers, and aldosterone antagonists, especially in systolic heart failure.
• Diuretics are essential for symptom control but do not improve survival.
• Medication titration should be cautious, monitoring for adverse effects such as hyperkalemia, hypotension, and renal impairment.
• Newer agents like angiotensin receptor-neprilysin inhibitors (ARNIs) have shown mortality benefits.
• Use of medications must be tailored based on ejection fraction, comorbidities, and patient response.

💡 Key Takeaway

Effective pharmacological treatment of heart failure involves a combination of drugs that improve survival and quality of life, with ACE inhibitors and beta-blockers forming the foundation of therapy, complemented by diuretics and other agents as needed.

📖 7. Non-Pharmacological Management

🔑 Key Concepts & Definitions

• Lifestyle Modifications: Behavioral changes such as sodium restriction, fluid management, weight control, smoking cessation, and regular physical activity aimed at reducing heart failure symptoms and progression.

• Dietary Sodium Restriction: Limiting sodium intake (usually <2 grams/day) to decrease fluid retention and reduce cardiac workload.

• Fluid Restriction: Limiting daily fluid intake (commonly 1.5-2 liters) to prevent volume overload in patients with significant congestion.

• Physical Activity: Tailored exercise programs that improve functional capacity and quality of life without overexerting the heart.

• Patient Education: Informing patients about symptom monitoring, medication adherence, lifestyle changes, and when to seek medical attention.

• Device Therapy & Surgical Interventions: Use of implantable devices (e.g., ICD, CRT) and surgical options (e.g., valve repair) as non-pharmacological strategies to improve cardiac function and prevent arrhythmias.

📝 Essential Points

• Non-pharmacological management complements medication therapy and is vital for symptom control, slowing disease progression, and improving quality of life.
• Sodium and fluid restrictions are critical in managing volume overload and preventing hospitalization.
• Regular physical activity, as tolerated, enhances cardiovascular health but should be individualized.
• Patient education improves adherence, early detection of worsening symptoms, and reduces hospital readmissions.
• Lifestyle modifications, including smoking cessation and weight management, significantly impact disease trajectory.
• Device therapy (like CRT and ICD) is indicated in specific heart failure populations to improve outcomes and prevent sudden cardiac death.
• Non-pharmacological strategies require ongoing assessment and reinforcement by healthcare providers.

💡 Key Takeaway

Non-pharmacological management of heart failure, emphasizing lifestyle changes, patient education, and device therapy, plays a crucial role in symptom control, reducing hospitalizations, and enhancing overall patient well-being.

📖 8. ECG Basics

🔑 Key Concepts & Definitions

• Electrocardiogram (ECG): A non-invasive recording of the heart's electrical activity over time, displayed as waveforms, used to diagnose arrhythmias, ischemia, and structural abnormalities.

• P Wave: Represents atrial depolarization, normally upright and rounded; duration <120 ms.

• QRS Complex: Reflects ventricular depolarization; normally narrow (<120 ms), with a sharp, tall waveform.

• T Wave: Indicates ventricular repolarization; typically upright in most leads.

• PR Interval: Time from onset of P wave to start of QRS complex; normal range 120-200 ms, indicating atrioventricular conduction.

• QT Interval: Duration from start of QRS to end of T wave; normal <440 ms, representing total ventricular depolarization and repolarization.

📝 Essential Points

• The ECG provides critical information about heart rhythm, conduction pathways, and myocardial health.

• Normal sinus rhythm features a P wave before each QRS, consistent PR interval, and regular rhythm.

• Abnormalities such as widened QRS, absent P waves, or irregular rhythms suggest arrhythmias or conduction blocks.

• Key measurements (e.g., QRS duration, QT interval) help identify risks like bundle branch blocks or arrhythmogenic potential.

• Recognizing common patterns (e.g., atrial fibrillation, LBBB) is vital for diagnosis and management.

💡 Key Takeaway

Mastering ECG components and their normal ranges enables accurate interpretation of cardiac electrical activity, essential for diagnosing arrhythmias, conduction issues, and ischemic changes in cardiac nursing practice.

📖 9. ECG Waveform Components

🔑 Key Concepts & Definitions

• P Wave: Represents atrial depolarization; the electrical activity associated with atrial contraction. Normally upright and precedes the QRS complex.

• QRS Complex: Reflects ventricular depolarization; the electrical activity during ventricular contraction. It is typically narrow (less than 120 ms) and has a sharp, tall appearance.

• T Wave: Indicates ventricular repolarization; the recovery phase of the ventricles. Usually upright in most leads and follows the QRS complex.

• PR Interval: The period from the start of the P wave to the start of the QRS complex; indicates the time for electrical impulse to travel from atria to ventricles. Normal duration is 120-200 ms.

• QT Interval: Encompasses the time from the start of the QRS complex to the end of the T wave; reflects the total time for ventricular depolarization and repolarization. Normal QTc is less than 440 ms in men and 460 ms in women.

• Baseline (Isoelectric Line): The flat line between waves, representing periods of electrical neutrality; used as a reference point for measuring intervals and wave amplitudes.

📝 Essential Points

• The P wave should be smooth and rounded; abnormal P waves can indicate atrial enlargement or arrhythmias.

• The QRS complex duration and morphology help identify conduction abnormalities like bundle branch blocks.

• The T wave shape and direction can reveal electrolyte imbalances or ischemia; inverted T waves may suggest ischemia or infarction.

• Accurate measurement of PR and QT intervals is vital for diagnosing conduction delays and risk of arrhythmias.

• The baseline serves as a reference for identifying abnormal waveforms, ST segment deviations, and other abnormalities.

💡 Key Takeaway

The ECG waveform components—P wave, QRS complex, T wave, and intervals—are fundamental for interpreting cardiac electrical activity; understanding their normal appearance and variations is essential for detecting arrhythmias and conduction issues.

📖 10. ECG Abnormalities in HF

🔑 Key Concepts & Definitions

• Left Bundle Branch Block (LBBB): A conduction delay or block in the left bundle branch causing a widened QRS complex (>120 ms) with characteristic morphology, often associated with systolic heart failure and indicating dyssynchronous ventricular contraction.

• Atrial Fibrillation (AF): An irregular, often rapid heart rhythm originating from disorganized atrial activity, characterized by absent P waves and an irregularly irregular ventricular response; common in HF, worsening symptoms and prognosis.

• QRS Duration: The length of the QRS complex on ECG, representing ventricular depolarization; prolongation (>120 ms) suggests conduction abnormalities like bundle branch blocks, impacting cardiac efficiency.

• ST Segment Changes: Deviations in the ST segment (elevation or depression) indicating myocardial ischemia or injury; in HF, these may reflect ischemic stress or underlying coronary artery disease.

• P Wave Abnormalities: Changes in P wave morphology or duration indicating atrial enlargement or atrial arrhythmias; atrial enlargement is common in HF due to increased atrial pressure.

📝 Essential Points

• ECG abnormalities such as LBBB are common in systolic HF and can influence management, including the use of cardiac resynchronization therapy (CRT).
• Atrial fibrillation frequently coexists with HF, contributing to decreased cardiac output and increased thromboembolic risk.
• Prolonged QRS duration (>120 ms) indicates electrical dyssynchrony, which may be corrected with device therapy.
• Ischemic changes on ECG (e.g., ST segment deviations) can exacerbate HF symptoms and guide revascularization strategies.
• Recognizing atrial enlargement and conduction delays on ECG helps in assessing disease severity and tailoring treatment.

💡 Key Takeaway

ECG abnormalities in heart failure, such as bundle branch blocks and arrhythmias, are vital diagnostic and prognostic tools that influence treatment decisions, particularly regarding device therapy and management of arrhythmias.

📊 Synthesis Tables

Feature	Systolic Heart Failure (HFrEF)	Diastolic Heart Failure (HFpEF)
Ejection Fraction (EF)	Reduced (<40%)	Preserved (>50%)
Pathophysiology	Impaired ventricular contraction	Impaired ventricular relaxation and filling
Common Causes	Ischemic heart disease, MI, cardiomyopathies	Hypertension, obesity, aging
Clinical Manifestations	Pulmonary congestion, dyspnea, fatigue	Similar symptoms, often with preserved EF
Treatment Focus	ACE inhibitors, diuretics, beta-blockers	Managing comorbidities, diuretics as needed

Heart Failure Types	Left-sided Heart Failure	Right-sided Heart Failure
Primary Involvement	Left ventricle	Right ventricle
Main Symptoms	Pulmonary congestion, dyspnea, crackles	Systemic congestion, edema, JVD
Common Causes	Hypertension, ischemic heart disease	Left-sided failure, pulmonary hypertension
Clinical Signs	Pulmonary crackles, S3 gallop	JVD, peripheral edema, hepatomegaly

⚠️ Common Pitfalls & Confusions

1. Confusing systolic and diastolic HF with just symptoms; rely on EF for classification.
2. Overlooking right-sided failure signs when diagnosing left-sided HF.
3. Assuming all pulmonary symptoms indicate primary lung pathology; consider cardiac causes.
4. Misinterpreting BNP levels without considering renal function or obesity effects.
5. Neglecting to differentiate HF types when planning pharmacological therapy.
6. Using ECG findings alone to diagnose HF; always correlate with imaging and labs.
7. Overlooking the importance of echocardiography in differentiating HF types.
8. Ignoring the role of neurohormonal activation in pathophysiology and treatment.
9. Misinterpreting chest X-ray findings; cardiomegaly can be subtle.
10. Assuming diuretics alone are sufficient without addressing underlying causes.

✅ Exam Checklist

• Define heart failure and distinguish between systolic (HFrEF) and diastolic (HFpEF) types.
• Explain the pathophysiology of HF, including neurohormonal activation and remodeling.
• Identify clinical manifestations of left-sided and right-sided HF.
• List key diagnostic tests: echocardiogram, BNP, ECG, chest X-ray, labs.
• Interpret typical ECG waveform components and common abnormalities in HF.
• Describe pharmacological treatments: ACE inhibitors, beta-blockers, diuretics, aldosterone antagonists.
• Outline non-pharmacological management: lifestyle modifications, device therapy, transplant considerations.
• Recognize ECG abnormalities associated with HF: arrhythmias, conduction blocks, ischemic changes.
• Understand the significance of BNP levels and other laboratory markers.
• Differentiate between HF types based on EF and clinical presentation.
• Discuss the importance of echocardiography in diagnosis and management.
• Be aware of common pitfalls in diagnosing and managing HF.